Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kids battling serious transplant complication

NCT ID NCT07116031

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study is testing a drug called belumosudil in children aged 1 to 18 who have a serious condition called chronic graft-versus-host disease (cGVHD) after a bone marrow transplant. The goal is to find the right dose for younger children and see if the drug is safe and can help control the disease in kids who have already tried at least two other treatments. Participants will take the drug until their condition worsens, they need a new treatment, or they experience side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site Number : 0560001

    RECRUITING

    Leuven, 3000, Belgium

  • Investigational Site Number : 0560003

    RECRUITING

    Ghent, 9000, Belgium

  • Investigational Site Number : 1240002

    RECRUITING

    Toronto, Ontario, M5G 1X8, Canada

  • Investigational Site Number : 1560001

    RECRUITING

    Shanghai, 200040, China

  • Investigational Site Number : 1560002

    RECRUITING

    Suzhou, 215025, China

  • Investigational Site Number : 1560003

    RECRUITING

    Beijing, 100045, China

  • Investigational Site Number : 1560004

    RECRUITING

    Shenzhen, 518026, China

  • Investigational Site Number : 2500001

    RECRUITING

    Paris, 75019, France

  • Investigational Site Number : 2500002

    RECRUITING

    Marseille, 13885, France

  • Investigational Site Number : 2760001

    RECRUITING

    Berlin, 13353, Germany

  • Investigational Site Number : 3760001

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Investigational Site Number : 3760002

    RECRUITING

    Jerusalem, 9112001, Israel

  • Investigational Site Number : 3760003

    RECRUITING

    Ramat Gan, 5262100, Israel

  • Investigational Site Number : 3760004

    RECRUITING

    Petah Tikva, 4920235, Israel

  • Investigational Site Number : 3760005

    RECRUITING

    Haifa, 3109601, Israel

  • Investigational Site Number : 3800001

    RECRUITING

    Rome, Roma, 00165, Italy

  • Investigational Site Number : 5280001

    RECRUITING

    Utrecht, 3584 CS, Netherlands

  • Investigational Site Number : 7240001

    RECRUITING

    Barcelona, 08035, Spain

  • Investigational Site Number : 7240002

    RECRUITING

    Madrid, 28009, Spain

  • Investigational Site Number : 7240003

    RECRUITING

    Esplugues de Llobregat, Barcelona [Barcelona], 08950, Spain

  • Investigational Site Number : 8260002

    RECRUITING

    Newcastle upon Tyne, England, NE2 4HH, United Kingdom

  • Memorial Sloan Kettering Cancer Center - New York - York Avenue- Site Number : 8400001

    RECRUITING

    New York, New York, 10065, United States

  • Texas Children's Hospital- Site Number : 8400008

    RECRUITING

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

CHRONIC GRAFT VERSUS HOST DISEASE